← back to search

Peng Liu

Sun Yat-sen University · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Circular RNAs in diseases, MicroRNA in disease regulation, Cancer-related molecular mechanisms research, and Breast Cancer Treatment Studies.
h-index
26
citations
3,893
works
61
NIH funding
primary concept
email

Recent publications

[Histological Transformation from Non-small Cell Lung Cancer to Small Cell Lung Cancer Induced by Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review].
PubMed 2025cited by 0position: middledoi
Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer
MedComm 2024cited by 64position: middledoi
PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer
Cell Death Discovery 2024cited by 38position: middledoi
Circular hsa_circ_0020377 regulates KLF7 by targeting miR-194-5p to facilitate tumor cell malignant behaviors and glycolysis in oral squamous cell carcinoma progression
Functional & Integrative Genomics 2023cited by 8position: middledoi
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition
Molecular Cancer 2022cited by 209position: firstdoi
CircGFRA1 facilitates the malignant progression of HER‐2‐positive breast cancer via acting as a sponge of miR‐1228 and enhancing AIFM2 expression
Journal of Cellular and Molecular Medicine 2021cited by 64position: lastdoi
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
Therapeutic Advances in Medical Oncology 2020cited by 124position: middledoi
circGNB1 Facilitates Triple-Negative Breast Cancer Progression by Regulating miR-141-5p-IGF1R Axis
Frontiers in Genetics 2020cited by 74position: firstdoi
Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population‐based study
Cancer Medicine 2018cited by 103position: middledoi
Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a
Oncogene 2018cited by 70position: middledoi
Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis
European Journal of Surgical Oncology 2018cited by 70position: middledoi
Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer
Biomedicine & Pharmacotherapy 2017cited by 98position: middledoi
Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients
The Breast 2017cited by 36position: middledoi
miR-92a regulates the expression levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 3 via sirtuin 1 signaling in hydrogen peroxide-induced vascular smooth muscle cells
Molecular Medicine Reports 2017cited by 18position: firstdoi
The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer
The Breast 2016cited by 112position: middledoi
mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK
Oncotarget 2016cited by 72position: firstdoi
miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer
Cancer Letters 2014cited by 120position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Hailin Tang · Sun Yat-sen University12 papers (2014–2024)Xinhua Xie · Sun Yat-sen University6 papers (2016–2024)Xiaoming Xie · Nanchang University5 papers (2014–2018)Yutian Zou · Sun Yat-sen University5 papers (2018–2024)Feng Ye · Sichuan University4 papers (2016–2022)Xiaoming Xie · Johnson & Johnson (United States)4 papers (2016–2024)Shaoquan Zheng · Sun Yat-sen University4 papers (2018–2024)Xiangsheng Xiao · Sun Yat-sen University3 papers (2017–2022)Xiaojia Huang · Fujian Medical University3 papers (2016–2018)Xing Li · Kunming Medical University2 papers (2020–2021)Feng Ye · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2014–2020)Anli Yang · Sun Yat-sen University2 papers (2020–2021)Lu Yang · Hainan Medical University2 papers (2014–2018)Yuhui Tang · Sun Yat-sen University2 papers (2024–2024)Ping Yu · Zhejiang Gongshang University2 papers (2018–2018)Yanan Kong · Sun Yat-sen University2 papers (2016–2020)Zeyu Shuang · Sun Yat-sen University2 papers (2016–2017)Cailu Song · Sun Yat-sen University2 papers (2016–2018)Yuying Sun · Sun Yat-sen University2 papers (2024–2024)Weikai Xiao · Red Cross Hospital2 papers (2018–2018)